Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 5/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | DCPS | Q96C86 | 2/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621380 | 0.94 | MCHR1 (0.51) | IKBKBCHUKMCHR1XDHHTR2C | |
| SCHEMBL620849 | 0.94 | MCHR1 (0.51) | IKBKBCHUKMCHR1HTR2CCCNA2 | |
| SCHEMBL618003 | 0.92 | MCHR1 (0.52) | IKBKBCHUKMCHR1HTR2CCCNA2 | |
| SCHEMBL618548 | 0.90 | DHFR (0.52) | IKBKBCHUKMCHR1XDHHTR2C | |
| SCHEMBL620761 | 0.90 | IKBKB (0.50) | IKBKBCHUK | |
| SCHEMBL2414503 | 0.86 | MCHR1 (0.50) | IKBKBCHUKMCHR1RIPK1XDH | |
| SCHEMBL620568 | 0.84 | MCHR1 (0.56) | MCHR1XDHDCPSDHFR | |
| SCHEMBL623134 | 0.84 | DCPS (0.40) | IKBKBCHUKMCHR1RIPK1HTR2C | |
| SCHEMBL619980 | 0.83 | DCPS (0.41) | IKBKBCHUKDCPS | |
| SCHEMBL619309 | 0.82 | IKBKB (0.50) | IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8633186-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2573559-A1 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2568287-A2 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| CN-101779124-A | modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC | 2010-07-14 | — | — | CN | disclosed |
| EP-2062050-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | Senomyx, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | IKBKB 4815/4885CHUK 4561/4885MCHR1 82/4885 |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | IKBKB 4815/4885CHUK 4561/4885MCHR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.